2025 Taiwan guidelines on the drug therapy of lung cancer: Advanced non-squamous cell carcinoma with actionable oncogenic drivers.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: lung cancer
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
This paper reports specifically on the pharmacological treatment of advanced non-squamous cell lung cancer with actionable oncogenic drivers. Recommendations are categorized according to levels of evidence, from large randomized controlled trials (level of evidence [LoE] I) to expert opinion (LoE V).
Lung cancer remains the leading cause of cancer mortality both globally and in Taiwan.
APA
Wu SG, Ho CC (2026). 2025 Taiwan guidelines on the drug therapy of lung cancer: Advanced non-squamous cell carcinoma with actionable oncogenic drivers.. Journal of the Formosan Medical Association = Taiwan yi zhi. https://doi.org/10.1016/j.jfma.2026.02.009
MLA
Wu SG, et al.. "2025 Taiwan guidelines on the drug therapy of lung cancer: Advanced non-squamous cell carcinoma with actionable oncogenic drivers.." Journal of the Formosan Medical Association = Taiwan yi zhi, 2026.
PMID
41708470 ↗
Abstract 한글 요약
Lung cancer remains the leading cause of cancer mortality both globally and in Taiwan. Advances in systemic therapies have substantially improved outcomes for patients with lung cancer. Experts from six leading medical societies in Taiwan collaborated to develop this guideline on the pharmacological management of advanced lung cancer. This guideline focuses on first- and second-line treatments, including chemotherapy, targeted therapy, and immunotherapy, based on tumor histology, molecular profile, PD-L1 expression level, and disease stage. It aims to improve lung cancer outcomes by providing a clear and localized treatment framework tailored to the clinical practice setting in Taiwan. This paper reports specifically on the pharmacological treatment of advanced non-squamous cell lung cancer with actionable oncogenic drivers. Recommendations are categorized according to levels of evidence, from large randomized controlled trials (level of evidence [LoE] I) to expert opinion (LoE V).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Acquired L858R mutation following -TKI resistance in lung adenocarcinoma: a case report.
- Virtual screening of novel alkaloids as potent inhibitors for G2032R-mutant ROS1 kinase in non-small-cell lung cancer.
- Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
- Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer.
- Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.